86 related articles for article (PubMed ID: 24999209)
1. Lack of GOPC-ROS1 (FIG-ROS1) rearrangement in adult human gliomas.
Karayan-Tapon L; Cortes U; Rivet P; Jermidi C; Vassal G; Wager M; Taillandier L
Eur J Cancer; 2014 Sep; 50(13):2364-6. PubMed ID: 24999209
[No Abstract] [Full Text] [Related]
2. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.
Rimkunas VM; Crosby KE; Li D; Hu Y; Kelly ME; Gu TL; Mack JS; Silver MR; Zhou X; Haack H
Clin Cancer Res; 2012 Aug; 18(16):4449-57. PubMed ID: 22661537
[TBL] [Abstract][Full Text] [Related]
3. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.
Suehara Y; Arcila M; Wang L; Hasanovic A; Ang D; Ito T; Kimura Y; Drilon A; Guha U; Rusch V; Kris MG; Zakowski MF; Rizvi N; Khanin R; Ladanyi M
Clin Cancer Res; 2012 Dec; 18(24):6599-608. PubMed ID: 23052255
[TBL] [Abstract][Full Text] [Related]
4. Novel GOPC(FIG)-ROS1 fusion in a pediatric high-grade glioma survivor.
Kiehna EN; Arnush MR; Tamrazi B; Cotter JA; Hawes D; Robison NJ; Fong CY; Estrine DB; Han JH; Biegel JA
J Neurosurg Pediatr; 2017 Jul; 20(1):51-55. PubMed ID: 28387643
[TBL] [Abstract][Full Text] [Related]
5. GOPC-ROS1 Fusion Due to Microdeletion at 6q22 Is an Oncogenic Driver in a Subset of Pediatric Gliomas and Glioneuronal Tumors.
Richardson TE; Tang K; Vasudevaraja V; Serrano J; William CM; Mirchia K; Pierson CR; Leonard JR; AbdelBaki MS; Schieffer KM; Cottrell CE; Tovar-Spinoza Z; Comito MA; Boué DR; Jour G; Snuderl M
J Neuropathol Exp Neurol; 2019 Dec; 78(12):1089-1099. PubMed ID: 31626289
[TBL] [Abstract][Full Text] [Related]
6. Clinical Activity of Crizotinib in Lung Adenocarcinoma Harboring a Rare ZCCHC8-ROS1 Fusion.
Hicks JK; Boyle T; Albacker LA; Madison R; Frampton G; Creelan BC
J Thorac Oncol; 2018 Aug; 13(8):e148-e150. PubMed ID: 30049378
[No Abstract] [Full Text] [Related]
7. Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21).
Charest A; Lane K; McMahon K; Park J; Preisinger E; Conroy H; Housman D
Genes Chromosomes Cancer; 2003 May; 37(1):58-71. PubMed ID: 12661006
[TBL] [Abstract][Full Text] [Related]
8. GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types.
Sievers P; Stichel D; Sill M; Schrimpf D; Sturm D; Selt F; Ecker J; Kazdal D; Miele E; Kranendonk MEG; Tops BBJ; Kohlhof-Meinecke P; Beschorner R; Kramm CM; Hasselblatt M; Reifenberger G; Capper D; Wesseling P; Stenzinger A; Milde T; Korshunov A; Witt O; Pfister SM; Wick W; von Deimling A; Jones DTW; Sahm F
Acta Neuropathol; 2021 Dec; 142(6):1065-1069. PubMed ID: 34536122
[No Abstract] [Full Text] [Related]
9. ROS kinase fusions are not common in Chinese patients with cholangiocarcinoma.
Liu P; Wu Y; Sun L; Zuo Q; Shi M
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Apr; 33(4):474-8. PubMed ID: 23644102
[TBL] [Abstract][Full Text] [Related]
10. Zeroing in on ROS1 rearrangements in non-small cell lung cancer.
Stumpfova M; Jänne PA
Clin Cancer Res; 2012 Aug; 18(16):4222-4. PubMed ID: 22859716
[TBL] [Abstract][Full Text] [Related]
11. GOPC-ROS1 Rearrangement as an Acquired Resistance Mechanism to Osimertinib and Responding to Crizotinib Combined Treatments in Lung Adenocarcinoma.
Zeng L; Yang N; Zhang Y
J Thorac Oncol; 2018 Jul; 13(7):e114-e116. PubMed ID: 29935846
[No Abstract] [Full Text] [Related]
12. Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.
Davare MA; Henderson JJ; Agarwal A; Wagner JP; Iyer SR; Shah N; Woltjer R; Somwar R; Gilheeney SW; DeCarvalo A; Mikkelson T; Van Meir EG; Ladanyi M; Druker BJ
Clin Cancer Res; 2018 Dec; 24(24):6471-6482. PubMed ID: 30171048
[TBL] [Abstract][Full Text] [Related]
13. Identification of a novel KLC1-ROS1 fusion in a case of pediatric low-grade localized glioma.
Nakano Y; Tomiyama A; Kohno T; Yoshida A; Yamasaki K; Ozawa T; Fukuoka K; Fukushima H; Inoue T; Hara J; Sakamoto H; Ichimura K
Brain Tumor Pathol; 2019 Jan; 36(1):14-19. PubMed ID: 30350109
[TBL] [Abstract][Full Text] [Related]
14. Novel
Deland L; Keane S; Bontell TO; Fagman H; Sjögren H; Lind AE; Carén H; Tisell M; Nilsson JA; Ejeskär K; Sabel M; Abel F
Cancer Genomics Proteomics; 2022; 19(6):711-726. PubMed ID: 36316040
[TBL] [Abstract][Full Text] [Related]
15. Identification of ROS1 rearrangement in gastric adenocarcinoma.
Lee J; Lee SE; Kang SY; Do IG; Lee S; Ha SY; Cho J; Kang WK; Jang J; Ou SH; Kim KM
Cancer; 2013 May; 119(9):1627-35. PubMed ID: 23400546
[TBL] [Abstract][Full Text] [Related]
16. ROS1 fusions in cancer: a review.
Uguen A; De Braekeleer M
Future Oncol; 2016 Aug; 12(16):1911-28. PubMed ID: 27256160
[TBL] [Abstract][Full Text] [Related]
17. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
[TBL] [Abstract][Full Text] [Related]
18. ROS1 Alterations as a Potential Driver of Gliomas in Infant, Pediatric, and Adult Patients.
Meredith DM; Cooley LD; Dubuc A; Morrissette J; Sussman RT; Nasrallah MP; Rathbun P; Yap KL; Wadhwani N; Bao L; Wolff DJ; Ida C; Sukhanova M; Horbinski C; Jennings LJ; Farooqi M; Gener M; Ginn K; Kam KL; Sasaki K; Kanagal-Shamanna R; Alexandrescu S; Brat D; Lu X
Mod Pathol; 2023 Nov; 36(11):100294. PubMed ID: 37532182
[TBL] [Abstract][Full Text] [Related]
19. ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases.
Yoshida A; Kohno T; Tsuta K; Wakai S; Arai Y; Shimada Y; Asamura H; Furuta K; Shibata T; Tsuda H
Am J Surg Pathol; 2013 Apr; 37(4):554-62. PubMed ID: 23426121
[TBL] [Abstract][Full Text] [Related]
20. ROS1 gene rearrangement is identified in NSCLC.
Cancer Discov; 2012 Feb; 2(2):OF9. PubMed ID: 22585869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
